Company / CapEx per Share
Intellia Therapeutics, Inc. CapEx per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest CapEx per Share
$0.01
FY2025
5-year range
$0.01 / $0.19
FY2021-FY2025
Trend
-82.2%
vs FY2024
Sector context
#137 of 142
Health Care
What the data says
Among 142 Health Care companies, Intellia Therapeutics, Inc. is in the bottom 4% for capex per share. CapEx per Share has declined for 4 consecutive years, from $0.19 in FY2021 to $0.01 in FY2025.
Based on SEC 10-K filings.
0.01 in FY2025 with a 5-year CAGR of -31.1%.
Declined from $0.16 to $0.01 over the past 2 years.
Health Care sector context is included.
CapEx per Share over time
Growth rates
- 3-Year CAGR
- -60.7%
- 5-Year CAGR
- -31.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 4% in Health CareTop 96% of 142This company $0.01 Sector average $1.70
▼
-99.3% below sector average
Key checks
Key Insights
- Intellia Therapeutics, Inc.'s capex per share has declined for 4 consecutive years.
- In FY2025, capex per share decreased 82.2% year-over-year.
- Ranks #137 out of 142 companies in the Health Care sector.
- Peak capex per share was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.14 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | CapEx per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.01 | -82.2% |
| FY2024 | $0.06 | -61.3% |
| FY2023 | $0.16 | -11.8% |
| FY2022 | $0.18 | -5.5% |
| FY2021 | $0.19 | +169.7% |
| FY2020 | $0.07 | -52.5% |
| FY2019 | $0.15 | +0.1% |
| FY2018 | $0.15 | -46.5% |
| FY2017 | $0.28 | +1.0% |
| FY2016 | $0.28 | -97.4% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026